Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: A randomized clinical trial

JAMA Psychiatry

Volumn 71, Issue 6, 2014, Pages 681-688

  Feder, Adriana ^a   Parides, Michael K ^a   Murrough, James W ^a   Perez, Andrew M ^a   Morgan, Julia E ^a   Saxena, Shireen ^b   Kirkwood, Katherine ^a   Aan Het Rot, Marije ^c   Lapidus, Kyle A B ^a   Wan, Le Ben ^a   Iosifescu, Dan ^a   Charney, Dennis S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; KETAMINE; MIDAZOLAM; PLACEBO;

ADULT; ARTICLE; BLURRED VISION; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL GLOBAL IMPRESSION SCALE IMPROVEMENT SCALE; CONTROLLED STUDY; COORDINATION DISORDER; CROSSOVER PROCEDURE; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELEVATED BLOOD PRESSURE; FATIGUE; FEMALE; HEADACHE; HUMAN; IMPACT EVENT SCALE REVISED; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SAFETY; TREATMENT OUTCOME; UNITED STATES; VOMITING; XEROSTOMIA;

ADMINISTRATION, INTRAVENOUS; ADULT; ANTI-ANXIETY AGENTS; CHRONIC DISEASE; CROSS-OVER STUDIES; DEPRESSION; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; MIDAZOLAM; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84902132275     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2014.62     Document Type: Article

References (39)

1. Kessler RC, Sonnega A, Bromet E, HughesM, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52(12):1048-1060.
2. Breslau N, Kessler RC, Chilcoat HD, Schultz LR, Davis GC, Andreski P. Trauma and posttraumatic stress disorder in the community: the 1996 Detroit Area Survey of Trauma. Arch Gen Psychiatry. 1998; 55(7):626-632. (Pubitemid 28340351)
3. Ravindran LN, Stein MB. Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Res. 2009;1293:24-39.
4. Jeffreys M, Capehart B, Friedman MJ. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J Rehabil Res Dev. 2012;49(5):703-715.
5. Committee on Treatment of Posttraumatic Stress Disorder; Board on Population Health and Public Health Practice; Institute of Medicine. Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence.Washington, DC: National Academies Press; 2008.
6. Nair J, Singh Ajit S. The role of the glutamatergic system in posttraumatic stress disorder. CNS Spectr. 2008;13(7):585-591.
7. Riaza Bermudo-Soriano C, Perez-Rodriguez MM, Vaquero-Lorenzo C, Baca-Garcia E. New perspectives in glutamate and anxiety. Pharmacol Biochem Behav. 2012;100(4):752-774.
8. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. (Pubitemid 44188478)
9. Mathew SJ, Shah A, Lapidus K, et al. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs. 2012;26(3):189-204.
10. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013; 170(10):1134-1142.
11. Fabbri LP, Batacchi S, Linden M, et al. Anaesthesia for urological endoscopic procedures in adult outpatients. Eur J Anaesthesiol. 1995;12(3): 319-324.
12. Strayer RJ, Nelson LS. Adverse events associated with ketamine for procedural sedation in adults. Am J Emerg Med. 2008;26(9):985-1028.
13. Duncan EJ, Madonick SH, Parwani A, et al. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology. 2001;25(1): 72-83. (Pubitemid 32493823)
14. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199- 214. (Pubitemid 24081509)
15. SchönenbergM, Reichwald U, Domes G, Badke A, Hautzinger M. Effects of peritraumatic ketamine medication on early and sustained posttraumatic stress symptoms in moderately injured accident victims. Psychopharmacology (Berl). 2005;182(3): 420-425. (Pubitemid 41464654)
16. SchönenbergM, Reichwald U, Domes G, Badke A, Hautzinger M. Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims. J Psychopharmacol. 2008;22(5): 493-497.
17. McGhee LL, Maani CV, Garza TH, Gaylord KM, Black IH. The correlation between ketamine and posttraumatic stress disorder in burned service members. J Trauma. 2008;64(2 suppl):S195-S198; Discussion S197-S198.
18. Zeng MC, NiciuMJ, Luckenbaugh DA, et al. Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. Biol Psychiatry. 2013;73(12):e37-e38.
19. D'Andrea D, Andrew Sewell R. Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion. Biol Psychiatry. 2013;74(9):e13-e14.
20. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Research Version (Patient Edition) (SCID-I/P). New York, NY: Biometrics Research Dept, Columbia University at NYSPI; 2002.
21. Weathers FW, Keane TM, Davidson Jr. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety. 2001;13 (3):132-156. (Pubitemid 32467173)
22. Weiss DS, Marmar CR. The Impact of Event Scale-Revised. In:Wilson J, Keane TM, eds. Assessing Psychological Trauma and PTSD. New York, NY: Guilford; 1996:399-411.
23. Montgomery SA, AsbergM. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389. (Pubitemid 9136500)
24. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-583. (Pubitemid 37289444)
25. GuyW. ECDEU Assessment Manual for Psychopharmacology-Revised, 1976. Rockville, MD; US Dept of Health, Education, andWelfare; Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
26. Rush AJ, FavaM,Wisniewski SR, et al; STAR&z.ast;D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR&z.ast;D): rationale and design. Control Clin Trials. 2004;25(1): 119-142. (Pubitemid 38230109)
27. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125-136. (Pubitemid 28097797)
28. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988;24:97-99.
29. Young RC, Biggs JT, Ziegler VE,Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435. (Pubitemid 9006756)
30. VA/DoD Clinical Practice Guidelines: management of post-traumatic stress disorder and acute stress reaction (2010). US Department of Veterans Affairs web site. http://www.healthquality .va.gov/ptsd/. Accessed March 11, 2014.
31. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry. 1990;51(6):236-238. (Pubitemid 20209219)
32. Cates ME, Bishop MH, Davis LL, Lowe JS, Woolley TW. Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother. 2004;38(9):1395-1399. (Pubitemid 39100190)
33. López-Muñoz F, Alamo C, García-García P. The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs. J Anxiety Disord. 2011;25(4):554- 562.
34. Dubovsky SL. Approaches to developing new anxiolytics and antidepressants. J Clin Psychiatry. 1993;54(suppl):75-83. (Pubitemid 23191289)
35. Steckler T, Risbrough V. Pharmacological treatment of PTSD - established and new approaches. Neuropharmacology. 2012;62(2):617- 627.
36. Yuen EY,Wei J, LiuW, Zhong P, Li X, Yan Z. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron. 2012;73(5): 962-977.
37. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338(6103):68-72.
38. Li N, Lee B, Liu RJ, et al.mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959- 964.
39. Li N, Liu RJ, Dwyer JM, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69 (8):754-761.